| APP |
Report |
Q2 2026 Revenue |
BEAT |
pred ~$1.98B vs. cons $1.94B |
MEDIUM |
| APP |
Report |
Q2 2026 Adjusted EBITDA |
BEAT |
pred ~$1.68B vs. cons $1.63B |
MEDIUM |
| APP |
Report |
Q2 2026 EPS |
BEAT |
pred ~$3.90 vs. cons $3.74 |
MEDIUM |
| APP |
Guide |
Q3 2026 Revenue Guidance |
BETTER |
guide ~$2.10B vs. cons ~$2.05B (Q3 2026) |
LOW |
| APP |
Guide |
Q3 2026 Adjusted EBITDA Margin Guidance |
UNCHANGED |
guide ~84-85% vs. cons ~84.5% (Q3 2026) |
LOW |
| APP |
Guide |
Self-Serve Axon / Consumer Vertical Ramp Commentary |
UNKNOWN |
guide ~mid-teens % of ad revenue run-rate vs. cons ~10-12% assumed contribution (Q3 2026 exit rate) |
LOW |
| APP |
Return |
Day-1 residual (stock − beta × S&P 500) |
+9.0% |
— |
MEDIUM |
| APP |
Return |
5-day cumulative residual |
+4.0% (FADE) |
A likely clean beat-and-modest-raise triggers an initial short-covering/relief rally given how oversold and bearishly positioned the stock is into the print, but the self-serve Axon ramp is still nascent (partial-quarter contribution), management's own commentary flags a 'temporary' step-up in S&M/marketing spend tied to the global launch, and analysts will likely trim 2027 margin and growth assumptions even after a Q2/Q3 beat (implicit cuts embedded in updated models for opex tied to onboarding an unvetted global advertiser base). That out-period math — margin dilution risk, deceleration comps, and lingering SEC/insider-selling overhang — should pull part of the initial pop back over the following days, consistent with a fade rather than full follow-through. |
MEDIUM |